IVX Stock Overview
Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.011|
|52 Week High||AU$0.034|
|52 Week Low||AU$0.008|
|1 Month Change||10.00%|
|3 Month Change||22.22%|
|1 Year Change||-15.38%|
|3 Year Change||-21.43%|
|5 Year Change||175.00%|
|Change since IPO||-97.21%|
Recent News & Updates
We're Not Very Worried About Invion's (ASX:IVX) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
|IVX||AU Pharmaceuticals||AU Market|
Return vs Industry: IVX exceeded the Australian Pharmaceuticals industry which returned -23.8% over the past year.
Return vs Market: IVX underperformed the Australian Market which returned -8% over the past year.
|IVX Average Weekly Movement||16.1%|
|Pharmaceuticals Industry Average Movement||10.8%|
|Market Average Movement||9.4%|
|10% most volatile stocks in AU Market||16.5%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: IVX is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: IVX's weekly volatility has decreased from 24% to 16% over the past year, but is still higher than 75% of Australian stocks.
About the Company
Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion’s IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer.
Invion Fundamentals Summary
|IVX fundamental statistics|
Is IVX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IVX income statement (TTM)|
|Cost of Revenue||AU$2.32m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.00034|
|Net Profit Margin||-68.09%|
How did IVX perform over the long term?See historical performance and comparison
Is IVX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IVX?
Other financial metrics that can be useful for relative valuation.
|What is IVX's n/a Ratio?|
Price to Sales Ratio vs Peers
How does IVX's PS Ratio compare to its peers?
|IVX PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
BOT Botanix Pharmaceuticals
LGP Little Green Pharma
VLS Vita Life Sciences
Price-To-Sales vs Peers: IVX is expensive based on its Price-To-Sales Ratio (21.6x) compared to the peer average (8.4x).
Price to Earnings Ratio vs Industry
How does IVX's PE Ratio compare vs other companies in the AU Pharmaceuticals Industry?
Price-To-Sales vs Industry: IVX is expensive based on its Price-To-Sales Ratio (21.6x) compared to the Australian Pharmaceuticals industry average (8.7x)
Price to Sales Ratio vs Fair Ratio
What is IVX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||21.6x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate IVX's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of IVX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IVX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IVX's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Invion forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Invion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has Invion performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IVX is currently unprofitable.
Growing Profit Margin: IVX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IVX is unprofitable, but has reduced losses over the past 5 years at a rate of 22.4% per year.
Accelerating Growth: Unable to compare IVX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IVX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.4%).
Return on Equity
High ROE: IVX has a negative Return on Equity (-11.45%), as it is currently unprofitable.
Discover strong past performing companies
How is Invion's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IVX's short term assets (A$8.6M) exceed its short term liabilities (A$462.4K).
Long Term Liabilities: IVX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: IVX is debt free.
Reducing Debt: IVX has no debt compared to 5 years ago when its debt to equity ratio was 31%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IVX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IVX has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 16.9% each year.
Discover healthy companies
What is Invion current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Invion Dividend Yield vs Market|
|Market Bottom 25% (AU)||2.8%|
|Market Top 25% (AU)||7.0%|
|Industry Average (Pharmaceuticals)||2.5%|
|Analyst forecast in 3 Years (Invion)||n/a|
Notable Dividend: Unable to evaluate IVX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IVX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IVX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IVX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IVX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Thian Chew has been Executive Chairman and Chief Executive Officer at Invion Limited since November 1, 2020 and also served as Interim Chief Executive Officer since October 31, 2020 until November 1, 2...
CEO Compensation Analysis
|Thian Chew's Compensation vs Invion Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||AU$2m||AU$309k|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||AU$368k||AU$266k|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||AU$194k||n/a|
|Dec 31 2019||n/a||n/a|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||AU$138k||n/a|
|Dec 31 2018||n/a||n/a|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||AU$53k||n/a|
Compensation vs Market: Thian's total compensation ($USD976.45K) is above average for companies of similar size in the Australian market ($USD276.84K).
Compensation vs Earnings: Thian's compensation has increased whilst the company is unprofitable.
Experienced Management: IVX's management team is considered experienced (2 years average tenure).
Experienced Board: IVX's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Invion Limited's employee growth, exchange listings and data sources
- Name: Invion Limited
- Ticker: IVX
- Exchange: ASX
- Founded: 2000
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$77.041m
- Shares outstanding: 6.42b
- Website: https://www.inviongroup.com
Number of Employees
- Invion Limited
- 100 Albert Road
- Level 4
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|7C8||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Feb 2010|
|IVIX.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Feb 2010|
|IVX||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Feb 2010|
|IVX||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Feb 2010|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/05 00:00|
|End of Day Share Price||2022/10/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.